查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612964

慢性頑固性咳嗽市場：按藥物類型、分銷管道分類 - 全球預測 2025-2030

Chronic Refractory Cough Market by Drug Type (Amitriptyline, Gabapentin, Pregabalin), Distribution Channel (Drug Store, Hospital Pharmacies, Online Pharmacies) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

慢性頑固性咳嗽市場2023年估值為55.7億美元，預計到2024年將達到58.8億美元，複合年成長率為5.88%，預計到2030年將達到83.2億美元。

慢性難治性咳嗽 (CRC) 是一種持續性咳嗽，對標準治療沒有反應，並且常常影響生活品質。 CRC 的範圍和定義著重於持續超過 8 週且對治療性介入或潛在疾病管理有抵抗力的咳嗽特徵。對有效的結直腸癌治療的需求源自於與未經治療的症狀相關的顯著的患者不適和醫療費用。最終用途範圍包括針對神經通路、咳嗽反射調節和細胞激素受體拮抗作用的潛在治療方法，主要相關人員包括製藥公司、研究機構和醫療保健提供者。

主要市場統計
基準年[2023] 55.7億美元
預測年份 [2024] 58.8億美元
預測年份 [2030] 83.2億美元
複合年成長率（%） 5.88%

CRC 市場的主要成長要素包括醫療保健專業人員對 CRC 認知的提高、診斷技術的進步以及對新型治療方法的研究投資的增加。容易患咳嗽相關疾病的人口老化將進一步影響市場擴張。最新的治療機會在於個人化醫療，其中基於遺傳和表現型分析的客製化治療有可能提高治療效果。對人工智慧主導的診斷工具和遠端醫療平台的投資也具有巨大潛力，可以實現遠端位置的有效 CRC 管理。

然而，市場成長受到諸如對結直腸癌病理生理學了解有限、研發成本高和嚴格的監管要求等挑戰的限制。咳嗽觸發因素的異質性使臨床試驗變得複雜，通常需要大規模和長期的研究。患者獲得醫療保健設施的機會有限，特別是在新興國家，進一步阻礙了市場開拓。

創新應著重於開發針對結直腸癌涉及的特定神經通路的標靶治療。對行為療法等非藥物干預措施的研究也有希望。生技公司和學術機構之間的合作可以加速突破性發現。最終，結直腸癌市場是一個利基但前景廣闊的領域的一個例子，科學創新和戰略夥伴關係可以取得重大進展，為改善患者治療結果和經濟可行性鋪平道路。

市場動態：揭示快速發展的慢性頑固性咳嗽市場的關鍵市場洞察

供需的動態交互作用正在改變慢性難治性咳嗽市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性頑固性咳嗽盛行率上升
    • 政府對認知和早期診斷的支持
  • 市場限制因素
    • 藥品召回的潛在風險
  • 市場機會
    • 增加有效藥物開發的舉措
    • 協同藥物開發和改善醫療費用
  • 市場挑戰
    • CRC 治療相關的副作用

波特五力：駕馭慢性難治性咳嗽市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解慢性頑固性咳嗽市場的外部影響

外部宏觀環境因素在塑造慢性頑固性咳嗽市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解慢性難治性咳嗽市場的競爭狀況

慢性頑固性咳嗽市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣供應商在慢性難治性咳嗽市場的績效評估

FPNV 定位矩陣是評估慢性難治性咳嗽市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了慢性頑固性咳嗽市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對慢性頑固性咳嗽市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性頑固性咳嗽盛行率增加
      • 政府對認知和早期診斷的支持
    • 抑制因素
      • 藥品召回的潛在風險
    • 機會
      • 加強有效藥物開發的研究和開發工作
      • 協作藥物開發和降低醫療成本
    • 任務
      • CRC 治療相關的副作用
  • 市場區隔分析
    • 藥物類型：探索Gabapentin作為治療神經病變相關慢性頑固性咳嗽的創新療法
    • 通路：慢性頑固性咳嗽網路藥局越來越受歡迎
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 慢性難治性咳嗽市場藥物按類型

  • 阿米替林
  • Gabapentin
  • Pregabalin

第7章慢性頑固性咳嗽市場：依通路分類

  • 藥局
  • 醫院藥房
  • 網路藥房

第8章 北美和南美慢性難治性咳嗽市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區慢性頑固性咳嗽市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲慢性難治性咳嗽市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 新型呼吸治療藥物投資快速增加：Notion Therapeutics 開發用於慢性頑固性咳嗽的 tupulcanium
    • Trevi Therapeutics 與 Haduvio 開始 2a 期 RIVER 試驗，推進難治性慢性咳嗽的治療
    • GSK PLC 完成對 BELLUS Health Inc. 的收購，增強慢性難治性咳嗽治療產品組合
  • 戰略分析和建議

公司名單

  • Accord Healthcare Inc.
  • Alitair Pharmaceuticals
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd
  • Bausch Health
  • Bayer AG
  • Cipla Inc.
  • Dr Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • GSK PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Mylan NV by Viatris Inc.
  • NeRRe Therapeutics
  • Novartis AG
  • Pfizer Inc.
  • Sienna Biotec
  • Strides Pharma
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Unichem Laboratories Ltd. by Ipca Labs
  • Zydus Pharmaceuticals USA Inc.
Product Code: MRR-9A2BA9536664

The Chronic Refractory Cough Market was valued at USD 5.57 billion in 2023, expected to reach USD 5.88 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 8.32 billion by 2030.

Chronic refractory cough (CRC) is a persistent cough that does not respond to standard treatments, often impacting quality of life. The scope and definition of CRC focus on its characterization as a cough lasting longer than eight weeks that remains resistant to therapeutic interventions or underlying condition management. The necessity for effective CRC treatments arises from the substantial patient discomfort and the healthcare costs associated with untreated symptoms. Applications and end-use scope include potential treatments targeting neural pathways, cough reflex modulation, and cytokine receptor antagonism, with key stakeholders including pharmaceutical companies, research institutions, and healthcare providers.

KEY MARKET STATISTICS
Base Year [2023] USD 5.57 billion
Estimated Year [2024] USD 5.88 billion
Forecast Year [2030] USD 8.32 billion
CAGR (%) 5.88%

Key growth factors in the CRC market include increasing awareness of CRC among healthcare professionals, advances in diagnostic technologies, and rising investment in research for novel therapeutic approaches. Aging populations, with a predisposition towards cough-related ailments, further influence market expansion. Latest opportunities lie in personalized medicine, where tailored treatments based on genetic and phenotypic profiling could enhance therapeutic efficacy. Investing in AI-driven diagnostic tools and telemedicine platforms also presents significant potential, enabling effective CRC management remotely.

Nonetheless, market growth is constrained by challenges such as limited understanding of CRC's pathophysiology, high R&D costs, and stringent regulatory requirements. The heterogeneity of cough triggers complicates clinical trials, often requiring large-scale, long-term studies. Limited patient access to healthcare facilities, particularly in developing countries, further impedes market reach.

For innovation, focus should be on developing targeted therapeutics that address specific neural pathways involved in CRC. Research into non-pharmacological interventions, such as behavioral therapies, also holds promise. Collaborations between biotech firms and academic institutions can accelerate breakthrough discoveries. Ultimately, the CRC market exemplifies a niche yet promising area with the potential for significant advances through scientific innovation and strategic partnerships, paving the way for improved patient outcomes and financial viability.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Refractory Cough Market

The Chronic Refractory Cough Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic refractory cough
    • Government support for awareness and early diagnosis
  • Market Restraints
    • Potential risk of drug recall
  • Market Opportunities
    • Increasing R&D initiatives toward effective drug development
    • Collaborative drug development and improving healthcare expenditure
  • Market Challenges
    • Side effects associated CRC treatment

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Refractory Cough Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Refractory Cough Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Refractory Cough Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Refractory Cough Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Refractory Cough Market

A detailed market share analysis in the Chronic Refractory Cough Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Refractory Cough Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Refractory Cough Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Refractory Cough Market

A strategic analysis of the Chronic Refractory Cough Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Refractory Cough Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Inc., Alitair Pharmaceuticals, Amneal Pharmaceuticals Inc., Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Ltd, Bausch Health, Bayer AG, Cipla Inc., Dr Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V. by Viatris Inc., NeRRe Therapeutics, Novartis AG, Pfizer Inc., Sienna Biotec, Strides Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd. by Ipca Labs, and Zydus Pharmaceuticals USA Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Refractory Cough Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Amitriptyline, Gabapentin, and Pregabalin.
  • Based on Distribution Channel, market is studied across Drug Store, Hospital Pharmacies, and Online Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic refractory cough
      • 5.1.1.2. Government support for awareness and early diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of drug recall
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D initiatives toward effective drug development
      • 5.1.3.2. Collaborative drug development and improving healthcare expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated CRC treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
    • 5.2.2. Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Refractory Cough Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Amitriptyline
  • 6.3. Gabapentin
  • 6.4. Pregabalin

7. Chronic Refractory Cough Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Drug Store
  • 7.3. Hospital Pharmacies
  • 7.4. Online Pharmacies

8. Americas Chronic Refractory Cough Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Chronic Refractory Cough Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Chronic Refractory Cough Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough
    • 11.3.2. Trevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment
    • 11.3.3. GSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accord Healthcare Inc.
  • 2. Alitair Pharmaceuticals
  • 3. Amneal Pharmaceuticals Inc.
  • 4. Apotex Inc.
  • 5. AstraZeneca PLC
  • 6. Aurobindo Pharma Ltd
  • 7. Bausch Health
  • 8. Bayer AG
  • 9. Cipla Inc.
  • 10. Dr Reddy's Laboratories Ltd.
  • 11. Glenmark Pharmaceuticals Ltd.
  • 12. GSK PLC
  • 13. Hikma Pharmaceuticals PLC
  • 14. Intas Pharmaceuticals Ltd.
  • 15. Mylan N.V. by Viatris Inc.
  • 16. NeRRe Therapeutics
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sienna Biotec
  • 20. Strides Pharma
  • 21. Sun Pharmaceutical Industries Ltd
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. Torrent Pharmaceuticals Ltd.
  • 24. Unichem Laboratories Ltd. by Ipca Labs
  • 25. Zydus Pharmaceuticals USA Inc.

LIST OF FIGURES

  • FIGURE 1. CHRONIC REFRACTORY COUGH MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC REFRACTORY COUGH MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC REFRACTORY COUGH MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC REFRACTORY COUGH MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY AMITRIPTYLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY GABAPENTIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY PREGABALIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC REFRACTORY COUGH MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM CHRONIC REFRACTORY COUGH MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. CHRONIC REFRACTORY COUGH MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. CHRONIC REFRACTORY COUGH MARKET, FPNV POSITIONING MATRIX, 2023